ClinicalTrials.gg
CompletedNCT06157255Updated May 29, 2024

An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

A Phase 1 interventional study of AZD4604 Inhalation Powder, 1 mg and [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL) in Asthma, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
245th of 248
8 · median 175
Started
2024
with 25 others
Phase 1
46 of 359
none open now
Registered
308th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 245th largest by enrollment of the 248 interventional ones that give a count, is one of 26 that started in 2024, is one of 46 in phase 1, and was the 308th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The Sponsor is developing the test medicine, AZD4604, as a potential treatment for asthma. Asthma is a common lung condition caused by inflammation (swelling) of the breathing tubes that carry air in and out of the lungs, causing occasional breathing difficulties such as wheezing, shortness of breath, chest tightness and cough.

This study in healthy volunteers will explore the following questions.

  • Does the test medicine cause any important side effects?
  • What are the blood levels of the test medicine and how quickly does the body get rid of it?
  • How much of the test medicine gets into the bloodstream?
  • How does the body break down and get rid of the test medicine?

This study will take place at one non-NHS site in Nottingham, and plans to enrol 8 healthy men and women aged 18-65 years who will be involved in both parts of the study.

Read the detailed description

The Sponsor is developing the test medicine, AZD4604, as a potential treatment for asthma. Asthma is a common lung condition caused by inflammation (swelling) of the breathing tubes that carry air in and out of the lungs, causing occasional breathing difficulties such as wheezing, shortness of breath, chest tightness and cough.

In this study, healthy volunteers will be given single doses of test medicine to find out how the body breaks down and gets rid of the test medicine. Two doses of the test medicine will be 'radiolabelled' - they will contain a small amount of radioactivity (Carbon-14) - so that it can be tracked in the body.

This study in healthy volunteers will explore the following questions.

  • Does the test medicine cause any important side effects?
  • What are the blood levels of the test medicine and how quickly does the body get rid of it?
  • How much of the test medicine gets into the bloodstream?
  • How does the body break down and get rid of the test medicine?

This study will take place at one non-NHS site in Nottingham.

It plans to enrol 8 healthy men and women aged 18-65 years who will be involved in both parts of the study.

In Part 1, volunteers will receive a dose of test medicine containing a very tiny amount of radio label, by injection into a vein, shortly followed by a single inhaled dose of the test medicine. In Part 2, volunteers will receive a dose of test medicine containing a very tiny amount of radio label, by mouth. In both parts volunteers will stay in the clinic for 15 nights, there will be a minimum 21 day washout period between each study part, and it will take up to 13 weeks to finish the study. A follow-up phone call will be conducted 6 to 10 days after discharge from Part 2.

Blood and urine samples will be collected to do safety tests. Over a period of at least 15 days for each part, many blood samples will be taken and volunteers will collect all their urine and faeces so that the amount of test medicine and its breakdown products can be measured.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures
  • Must be willing and able to communicate and participate in the whole study
  • Healthy males or non-pregnant, non-lactating healthy female subjects aged 18 to 65 years inclusive at the time of signing informed consent
  • Females must have a negative serum pregnancy test at screening and a negative urine pregnancy test on admission to the unit, must not be lactating and not intending to become pregnant during their study participation, confirmed at screening and admission/pre-dose and fulfil the criteria detailed in the Clinical Protocol
  • Must agree to adhere to the requirements defined in the Clinical Protocol
  • (BMI) between 18.0 and 30.0 kg/m2 inclusive and weight at least 50 kg and no more than 100 kg inclusive
  • Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)
  • Screening/pre-dose >80% of the predicted value for their age, gender, height and race
  • Screening/pre-dose FEV1/forced vital capacity (FVC) >0.70

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder (e.g. cardiovascular pulmonary, GI, liver, renal, neurological, musculoskeletal ,endocrine, metabolic, malignant, psychiatric, major physical impairment, skin abnormalities and glucose metabolism abnormalities) which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study
  • History or presence of GI, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
  • Subjects with a history of asymptomatic gall stones
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP
  • History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4604. Hay fever is allowed unless it is active
  • History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or GI disease, neurological or psychiatric disorder, as judged by the investigator
  • Subjects with a milk or milk protein allergy
  • Subjects who have had any or neoplastic disease (except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured)
  • Subjects with history or any ongoing, chronic or recurrent infectious disease, herpes, or evidence of tuberculosis infection
  • Subjects with risk factors for thrombosis or any history of thrombosis
  • Subjects with a previous history of pneumonia (even if effectively treated)
  • History of infantile bronchiolitis, a history of asthma, adverse reaction or allergy to the inhaled medication AZD4604 or any
  • Upper respiratory tract infection (excluding otitis media) within 14 days of first admission, or lower respiratory tract infection within the last 3 months
  • Acute diarrhoea or constipation in the 7 days before the predicted first dosing date. If screening occurs >7 days before the first dosing date, this criterion will be determined on first dosing date. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than 3 times per day. Constipation will be defined as a failure to open the bowels less frequently than every other day.
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
  • Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis as judged by the investigator. Subjects with Gilbert's Syndrome are allowed.
  • Subjects with any of the following at screening:

White blood cell count ˂3.0 × 109/L ˂1.8 × 109/L Lymphocyte count ˂1.0 × 109/L

  • Any clinically significant abnormal findings in vital signs, at screening or pre-dose, as judged by the investigator
  • Any clinically significant abnormalities on 12-lead , at screening or pre-dose, as judged by the investigator
  • Any positive result at screening for serum surface antigen (HBsAg), virus antibody (HCV Ab), and (HIV) 1 and 2 antibody
  • Any positive QuantiFERON®-TB Gold test at screening
  • Subjects with \<(LLN + 1 g/dL) at screening
  • Evidence of renal impairment at screening, as indicated by an estimated (CLcr) of \<80 mL/min using the Cockcroft-Gault equation
  • Has received another new chemical or biologic entity (defined as a compound which has not been approved for marketing) within the 90 days prior to the planned first dosing date, or less than 5 elimination half-lives prior to the planned first dosing date, whichever is longer. Note: subjects consented and screened, but not randomised/enrolled in this study or a previous Phase I study, are not excluded
  • Subjects who report to have previously received AZD4604
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
  • Subjects who have been administered a [14C]-labelled IMP in an ADME study in the last 12 months
  • Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening
  • Use of any prescribed or non-prescribed medication including antacids, analgesics (other than up to 4 g of paracetamol/acetaminophen per day, hormonal ), herbal remedies, and megadose vitamins and minerals (intake of >3 times the recommended daily dose) during the two weeks prior to the first administration of IMP or longer if the medication has a long half-life Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the is such that no pharmacodynamic activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardise the safety of the trial subject; and if the use of medication is not considered to interfere with the objectives of the study.
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks or 5 half-lives, whichever is longer, prior to the first administration of IMP
  • Subjects who have received any live, attenuated or mRNA vaccine within 4 weeks prior to the first administration of IMP
  • Known or suspected history of alcohol or drug abuse in the past 2 years or excessive intake of alcohol (>21 units per week for men and >14 units per week for women [1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type]) or as judged by the investigator
  • A confirmed positive alcohol breath test at screening or admission
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening
  • A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
  • Confirmed positive drugs of abuse test result at screening or admission
  • Excessive intake of caffeine-containing drinks or food (e.g. coffee, tea, chocolate) as judged by the investigator. Excessive intake of caffeine defined as the regular consumption of more than 600 mg of caffeine per day (e.g. >5 cups of coffee) or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the site.
  • Male subjects with pregnant partners
  • Involvement of any Astra Zeneca, Quotient or study site employee or their close relatives
  • Judgment by the investigator that the volunteer should not participate in the study if they have any ongoing or recent (i.e. during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements
  • Subjects who cannot communicate reliably with the Investigator.
  • Vulnerable subjects, e.g. kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
  • Subjects who are unable to demonstrate effective inhalation technique with DPI at screening, Day -1 or pre-dose of Part 1 (if applicable)
  • Failure to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    AZD4604

    In Part 1, one 30 ug dose of \[14C\]AZD4604 Solution for Infusion 6 ug/mL (NMT 37.0 kBq/5 mL) and one 3 mg dose of AZD4604 Inhalation Powder, 1 mg (as 3 x 1 mg). In Part 2, one 4 mg dose of \[14C\]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq).

    Drug: AZD4604 Inhalation Powder, 1 mg · Drug: [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL) · Drug: [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)

Interventions

06

What researchers measure

Primary outcomes

  1. Amount of AZD4604 excreted (Ae) - Part 1

    Mass balance of total radioactivity (TR) of \[14C\]AZD4604 in urine and faeces

    Time frame: Urine and faecal sample collection from pre-dose to 336 hours post-dose

  2. Amount of AZD4604 excreted expressed as a fraction of dose excreted (Fe) - Part 1

    Mass balance of total radioactivity (TR) of \[14C\]AZD4604 in urine and faeces

    Time frame: Urine and faecal sample collection from pre-dose to 336 hours post-dose

  3. The cumulative amount of AZD4604 excreted (CumAe) - Part 1

    Mass balance of total radioactivity (TR) of \[14C\]AZD4604 in urine and faeces

    Time frame: Urine and faecal sample collection from pre-dose to 336 hours post-dose

  4. Cumulative amount of AZD4604 excreted expressed as a fraction of dose excreted (CumFe) - Part 1

    Mass balance of total radioactivity (TR) of \[14C\]AZD4604 in urine and faeces

    Time frame: Urine and faecal sample collection from pre-dose to 336 hours post-dose

  5. Time to maximum concentration (tmax) for AZD4604 and total radioactivity - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  6. Area under the curve from time 0 extrapolated to infinity for AZD4604 and total radioactivity (AUC-inf) - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  7. Maximum observed concentration (Cmax) for AZD4604 and total radioactivity - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  8. Area under the curve from time 0 to the time of the last measurable concentration for AZD4604 and total radioactivity (AUC0-t) - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  9. Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) and total radioactivity - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  10. Terminal elimination half-life of AZD4604 (t1/2) and total radioactivity - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  11. First order rate constant associated with the terminal (log-linear) portion of the curve for AZD4604 (λz) and total radioactivity - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  12. Total body clearance calculated after a single IV administration (CL) - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  13. Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  14. Volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single IV administration (Vz) - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  15. Volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) - Part 1

    PK of AZD4604 and \[14C\]AZD4604 in plasma

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  16. Assessment of metabolites in plasma, urine and faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry - Part 1

    Metabolite profiling and structural identification from plasma, urine and faecal samples

    Time frame: Plasma, urine and faces sample collection from pre-dose to 336 hours post-dose

  17. Amount of AZD4604 excreted (Ae) - Part 2

    Mass balance of total radioactivity (TR) of \[14C\]AZD4604 in urine and faeces

    Time frame: Urine and faecal sample collection from pre-dose to 336 hours post-dose

  18. Amount of AZD4604 excreted expressed as a fraction of dose excreted (Fe) - Part 2

    Mass balance of total radioactivity (TR) of \[14C\]AZD4604 in urine and faeces

    Time frame: Urine and faecal sample collection from pre-dose to 336 hours post-dose

  19. The cumulative amount of AZD4604 excreted (CumAe) - Part 2

    Mass balance of total radioactivity (TR) of \[14C\]AZD4604 in urine and faeces

    Time frame: Urine and faecal sample collection from pre-dose to 336 hours post-dose

  20. Cumulative amount of AZD4604 excreted expressed as a fraction of dose excreted (CumFe) - Part 2

    Mass balance of total radioactivity (TR) of \[14C\]AZD4604 in urine and faeces

    Time frame: Urine and faecal sample collection from pre-dose to 336 hours post-dose

  21. Time to maximum concentration (tmax) for AZD4604 and total radioactivity - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  22. Area under the curve from time 0 extrapolated to infinity for AZD4604 and total radioactivity (AUC-inf) - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  23. Maximum observed concentration (Cmax) for AZD4604 and total radioactivity - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  24. Area under the curve from time 0 to the time of the last measurable concentration for AZD4604 and total radioactivity (AUC0-t) - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  25. Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) and total radioactivity - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  26. Terminal elimination half-life of AZD4604 (t1/2) and total radioactivity - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  27. First order rate constant associated with the terminal (log-linear) portion of the curve for AZD4604 (λz) and total radioactivity - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  28. Total body clearance calculated after a single extravascular administration where F (fraction of dose bioavailable) is unknown (CL/F) - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  29. Volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single extravascular administration where F (fraction of dose bioavailable) is unknown (Vz/F) - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  30. Renal clearance calculated using plasma AUC of AZD4604 and total radioactivity - Part 2

    PK of AZD4604 in plasma and whole blood

    Time frame: Plasma and whole blood sample collection from pre-dose to 336 hours post-dose

  31. Assessment of metabolites in plasma, urine and faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry - Part 2

    Metabolite profiling and structural identification from plasma, urine and faecal samples

    Time frame: Plasma, urine and faces sample collection from pre-dose to 336 hours post-dose

Secondary outcomes

  1. Absolute bioavailability - Part 1

    Absolute bioavailability (Finh) based on AUC0-inf of inhaled administration compared to IV administration, adjusted for dose

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

  2. Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating TR and/or accounting for 10% or more of the dose in excreta

    Identification of chemical structure of each metabolite accounting for more than 10% of circulating TR or accounting for 10% more of the dose in urine and faeces

    Time frame: Urine and faecal sample collection from pre-dose to 336 hours post-dose

  3. Number of subjects with treatment-related adverse events - Part 1 and Part 2

    To provide additional safety and tolerability information for AZD4604 by assessing the incidence of AEs

    Time frame: Through study duration, approximately 13 weeks

  4. Blood:plasma concentration ratios - Part 2

    Blood:plasma concentration ratios of total radioactivity

    Time frame: Whole blood samples and plasma samples collected from pre-dose until 336 hours post-dose

  5. Absolute bioavailability - Part 2

    Absolute bioavailability (Finh) based on AUC0-inf of oral administration compared to IV administration, adjusted for dose

    Time frame: Plasma sample collection from pre-dose to 336 hours post-dose

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to teh EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-levels data in an approved sponsors tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the disclosure statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in May 2024, 3 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 5, 2023
StartActual
Feb 16, 2024
Primary completionActual
May 20, 2024
CompletionActual
May 20, 2024
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06157255
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Dec 5, 2023
Start date
Feb 16, 2024
Primary completion
May 20, 2024
Completion
May 20, 2024
Last update
May 29, 2024

Study contacts

Somasekhara Menakuru, MBBS, MS, MRCS, DPM, MFPM
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Londamocitinib

Start the discussion